Cite
MLA Citation
Andreas Wicki et al.. “First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13).” European journal of cancer, vol. 96, 2018, pp. 6–16. http://access.bl.uk/ark:/81055/vdc_100062167691.0x000022